| __timestamp | Pfizer Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 14097000000 | 49315000 |
| Thursday, January 1, 2015 | 14809000000 | 75043000 |
| Friday, January 1, 2016 | 14837000000 | 83749000 |
| Sunday, January 1, 2017 | 14784000000 | 122682000 |
| Monday, January 1, 2018 | 14455000000 | 207761000 |
| Tuesday, January 1, 2019 | 14350000000 | 284812000 |
| Wednesday, January 1, 2020 | 11615000000 | 317875000 |
| Friday, January 1, 2021 | 12703000000 | 282660000 |
| Saturday, January 1, 2022 | 13677000000 | 451421000 |
| Sunday, January 1, 2023 | 14771000000 | 481871000 |
| Monday, January 1, 2024 | 14730000000 |
Unleashing the power of data
In the world of pharmaceuticals, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Pfizer Inc. and Sarepta Therapeutics, Inc. have demonstrated contrasting approaches. Pfizer, a global giant, consistently allocated around 14% of its revenue to SG&A, peaking in 2016. In contrast, Sarepta, a smaller biotech firm, increased its SG&A spending by nearly 900% from 2014 to 2023, reflecting its aggressive growth strategy. This divergence highlights the varied paths companies take in scaling operations and market presence. While Pfizer's spending remained relatively stable, Sarepta's surge underscores its commitment to expansion and innovation. As the pharmaceutical landscape evolves, these spending patterns offer insights into each company's strategic priorities and market positioning.
Cost Management Insights: SG&A Expenses for Pfizer Inc. and Sanofi
Pfizer Inc. and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Pfizer Inc. vs Catalent, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Pfizer Inc. and BioMarin Pharmaceutical Inc.
Pfizer Inc. and Geron Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Pfizer Inc. vs Evotec SE
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs ADMA Biologics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and CRISPR Therapeutics AG
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and PTC Therapeutics, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Soleno Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and MiMedx Group, Inc.